JPMorgan raised the firm’s price target on AbbVie (ABBV) to $235 from $200 and keeps an Overweight rating on the shares. The firm left its large cap biopharma estimates largely unchanged but increased price targets on a move to December 2026 from December 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie price target raised to $245 from $215 at Cantor Fitzgerald
- AbbVie price target raised to $240 from $215 at BMO Capital
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- AbbVie’s ABBV-1088 Study: A Closer Look at Recent Developments
- AbbVie’s Rinvoq Franchise Secures Extended Exclusivity, Boosting Long-Term Prospects and Justifying Buy Rating